Vortioxetine: A new alternative for the treatment of major depressive disorder.

Abstract

Major Depressive Disorder (MDD) is a serious psychiatric condition. Its treatment remains a challenge nowadays. Vortioxetine is a novel antidepressant with a unique profile, as it acts as a multimodal serotoninergic agent. Its efficacy in MDD has been established in many short- and long-term studies, with 7 positive, 4 negative and 1 failed randomized controlled trials. Moreover, its ability to modulate a wide range of neurotransmitters (serotonin, dopamine, norepinephrine, histamine, glutamate or GABA) confers vortioxetine pro-cognitive effects. Side effects are also different from conventional antidepressants, according to its low incidence of sexual dysfunction, weight gain or cardiovascular alterations. The aim of this systematic review is to describe the pharmacology, clinical efficacy and safety profile of vortioxetine, as well as its potential effectiveness in improving cognitive symptoms.

• Authors: Estela Salagre, Iria Grande, Brisa Solé, Jose Sanchez-Moreno, Eduard Vieta
• Journal: Revista de psiquiatria y salud mental (Rev Psiquiatr Salud Ment (Engl Ed)) 2018 Jan - Mar Vol. 11 Issue 1 Pg. 48-59 ISSN: 2173-5050 [Electronic] Spain
• Vernacular Title: Vortioxetina: una nueva alternativa en el trastorno depresivo mayor.
• PMID: 28800937 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2017 SEP y SEPB. Publicado por Elsevier España, S.L.U. All rights reserved.

Chemical References

• Antidepressive Agents
• Vortioxetine

Topics

• Antidepressive Agents (pharmacology, therapeutic use)
• Cognition (drug effects)
• Depressive Disorder, Major (drug therapy)
• Humans
• Treatment Outcome
• Vortioxetine (pharmacology, therapeutic use)